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Abstract
Introduction: Preeclampsia during pregnancy warrants therapy with low dose aspirin. The
purpose of this review is to investigate whether these women are at increased future risk for
cardiovascular morbidity and mortality, and if aspirin therapy should be continued following the
puerperium to prevent future cardiovascular events.
Research Questions: Do women who had preeclampsia during pregnancy, have increased future
cardiovascular morbidity and mortality?
Does continued aspirin use in postpartum women, who had preeclampsia during pregnancy,
decrease future cardiovascular morbidity and mortality outcomes?
Research Methods: Literature review was conducted utilizing CINAHL, Dynamed plus and
PubMed databases.
Discussion: It is found that further research is necessary to adequately assess if this demographic
is at risk. Many studies have found that preeclampsia does increase risk of cardiovascular
morbidity and mortality, but that this difference is not statistically significant until later decades
in life. There is also new evidence that the risks of bleeding from prophylactic aspirin therapy
outweigh the benefit of decreasing cardiovascular and ischemic events. Based on this
information, it is prudent to further research and study this group and stratify their risk as well as
researching if there is a better modality upon which to provide prophylaxis with lower risk than
benefit.
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Introduction
Preeclampsia is a diagnosis reserved for approximately 3-7% of pregnancies (Sarma et al,
2016). Preeclampsia is defined as hypertension during pregnancy, after 20 weeks, with the
presence of proteinuria. Preeclampsia increases risks during pregnancy due to hypertensive
effects on mother and fetus. For women with preeclampsia, there are set recommendations
including the use of 81 mg aspirin, daily, for prevention of negative fetal and maternal outcomes
during pregnancy. There are known harms of hypertension, to the general population.
Hypertension results in increased cardiovascular morbidity and mortality (Sutters, 2018). This
understanding would lead one to believe that having hypertension during pregnancy would lead
to future cardiovascular risks, despite the short time frame, as these patients with preeclampsia
have experienced vascular/endothelial injury. Currently, there is a lack of defined
recommendations for treatment beyond the post-partum period. This review will investigate if
continued treatment may help to reduce future cardiovascular risk in patients who have been
diagnosed with preeclampsia.
Statement of the Problem
Hypertension during preeclampsia leads to endothelial damage, which predisposes these
women to thrombotic and ischemic events. Currently, there are no set recommendations on how
to treat this high-risk group of women who had preeclampsia during a pregnancy. This
population, as well as healthcare providers, could be unaware of potential cardiovascular risks
and ways to prevent future cardiovascular events. Understanding, first, if this population is at
increased risk for future cardiovascular events, and two, if there is a treatment that decreases this
risk, helps us identify a population in which we can intervene to decrease future cardiovascular
morbidity and mortality.
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Research Question
Do women who had preeclampsia during pregnancy have increased future cardiovascular
morbidity and mortality?
Does continued aspirin use in postpartum women, who had preeclampsia during
pregnancy decrease future cardiovascular morbidity and mortality outcomes?
Research Methods
Research was conducted using the PubMed, Dynamed Plus and CINAHL databases.
Only studies published in English language are included.
The first search of CINAHL database using preeclampsia and endothelium and damage
resulted in 11 articles. Articles were excluded if they evaluated treatment of preeclampsia or
different effects of therapeutic modalities on preeclampsia. Articles were included if they
specifically extrapolated the effects that preeclampsia has on the endothelium.
A search of Dynamed Plus database using the search term Hypertensive disorders of
pregnancy resulted in one review. Under the subheadings Postpartum management then
prevention and screening, under Prevention there is a review of aspirin therapy. However, this
information provides conflicting evidence regarding when to start prophylactic aspirin therapy in
pregnancy for prevention of preeclampsia.
A primary search of PubMed using (“aspirin” [MeSH Terms] OR “aspirin” [All
Fields] AND (“postpartum period” [MeSH Terms] OR (“postpartum” [All Fields] AND
“Period” [All Fields]) OR “postpartum period” [All Fields]) produced 120 articles. Articles
were excluded if they did not include aspirin in relation to postpartum women, not for the
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treatment of preeclampsia during pregnancy. Other articles were excluded as they did not address
the research question.
A second search of PubMed using the search ("aspirin"[MeSH Terms] OR "aspirin"[All
Fields]) AND ("prevention and control"[Subheading] OR ("prevention"[All Fields] AND
"control"[All Fields]) OR "prevention and control"[All Fields] OR "prevention"[All Fields])
AND ("forecasting"[MeSH Terms] OR "forecasting"[All Fields] OR "future"[All Fields]) AND
("cardiovascular system"[MeSH Terms] OR ("cardiovascular"[All Fields] AND "system"[All
Fields]) OR "cardiovascular system"[All Fields] OR "cardiovascular"[All Fields]) AND
("risk"[MeSH Terms] OR "risk"[All Fields]) AND after[All Fields] AND ("preeclampsia"[MeSH Terms] OR "pre-eclampsia"[All Fields] OR "preeclampsia"[All Fields])
results in 2 articles. One is included due to applicability to the literature review and research
questions.
Lastly, a third search of PubMed using the search ("aspirin"[MeSH Terms] OR
"aspirin"[All Fields]) AND effect[All Fields] AND ("endothelium"[MeSH Terms] OR
"endothelium"[All Fields]) AND ("pre-eclampsia"[MeSH Terms] OR "pre-eclampsia"[All
Fields] OR "preeclampsia"[All Fields]) results in four articles. The article included had the most
clinical applicability and relevance to the stated problem and research questions.

Literature Review
The current literature available demonstrates there is an increased risk of future
cardiovascular disease in women who have had preeclampsia, when compared to women who
did not have preeclampsia during pregnancy. Preeclampsia is defined as hypertension during
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pregnancy, after the 20th week of gestation, with the presence of proteinuria (mayoclinic.org,
2018). This review will evaluate the effect of both preeclampsia and aspirin on the endothelium,
followed by long-term cardiovascular outcomes after preeclampsia, and finally will close with a
review of the literature on aspirin preventing future cardiovascular morbidity and mortality in
formerly preeclamptic women. Currently, there continues to be a need for further research as to
whether daily aspirin therapy can decrease cardiovascular risk in this population or if the risks of
continued aspirin therapy outweigh the benefits.
Preeclampsia effect on endothelium
Preeclampsia is a hypertensive disease of pregnancy that is accompanied by proteinuria
and in some cases edema. Many researchers continue to investigate the mechanisms that are at
fault in causing or predisposing certain women to developing preeclampsia during pregnancy,
and what effects preeclampsia has on the endothelium and risk for further vascular disease
processes. This can be difficult to determine as there are many theories trying to differentiate
maternal versus placental mechanisms at play (Chambers, et al., 2001).
Chambers et al., (2001), conducted a study in which they investigated various placental
and maternal factors that may contribute to the development of preeclampsia. In order to separate
maternal from placental factors contributing to preeclampsia and effects on the endothelium,
they included women who were a median of three years postpartum. Their study concluded that
“vascular endothelial dysfunction is recognized to be a central disturbance in preeclampsia”
(Chambers et al., 2001). These results demonstrate that it is dysfunction of the endothelium that
predisposes women to developing preeclampsia.
The strengths and limitations of this study both come from its design as a Case-control
study. As a case-control study, it is retrospective, and the subjects included have already been
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diagnosed with the disease being studied, in this case, preeclampsia. Another limitation is the
study population consists of 191 participants. Due to the relatively limited study population it
will be difficult to generalize these results to the general population. Also, the subjects were
chosen from hospital records from three different hospitals in London, England (Chambers et al.,
2001). Again, this can be a limitation as the results may be able to be generalized to those living
in London, however, due to potential influence of various environmental factors, it will be
difficult to generalize these results to those living outside of the London area.
The strengths of this study also come from the fact the design is a case-control study.
This study design allows the researchers to better extrapolate what risk factors are contributing to
the development of preeclampsia. This is beneficial to the medical community as it can help to
differentiate between the maternal or placental factors that may be causing preeclampsia.
Heidema et al., (2015), investigated history of preeclampsia versus obesity on developing
metabolic syndrome. Their study also found that women with a history of preeclampsia were
more inclined to develop metabolic syndrome, than their obese counterparts (Heidema et al.,
2015). The difference in the incidence of metabolic syndrome in formerly preeclamptic women
was statistically significant than that of the obese patients included in the study population
(P<.001), (Heidema et al., 2015). To make connections between the development of metabolic
syndrome as a result of endothelial dysfunction incurred during preeclampsia, more studies
would be necessary. However, as metabolic syndrome is defined “by a cluster of traditional
cardiometabolic abnormalities,” (Heidema et al., 2015), it may be reasonable to believe there is
some level of endothelial dysfunction contributing to the development of metabolic syndrome
and these cardiometabolic syndromes.
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Preeclampsia has a shearing effect on the endothelium as with other hypertensive
disorders; however, for this population, the blood pressure typically returns to normal parameters
following delivery. Chambers et al. (2001) acknowledges the endothelial injury is only transient
while the blood pressure is elevated. They used flow-mediated dilatation to assess vascular
endothelial function (Chambers et al., 2001). The results demonstrated that previously
preeclamptic women had a statistically significantly lower brachial artery flow-mediated
endothelium dilatation than the control group (P<.001) (Chambers et al., 2001). These results
combined with those of Spaanderman, et al. (2005), who evaluated platelet responsiveness
following preeclampsia, suggest that there is some level of endothelial dysfunction following
preeclampsia. Spaanderman et al. (2005) found that women who formerly had preeclampsia also
had a 15% increase in platelet responsiveness. Based on these findings in addition to other
platelet markers, they concluded there is some element of endothelial dysfunction that is unable
to accommodate the increased cardiovascular demands of pregnancy (Spaanderman et al., 2005).
Endothelial shear from high blood pressure is theorized to be an underlying mechanism in
hyperactive platelet activity in the preeclamptic patients in which they speculate this endothelial
damage increases the number of presensitized platelets circulating in these patients
(Spaanderman et al., 2005).
Heidema et al., (2015) conducted a retrospective case-control study. The benefits of this
study design is that the researchers are able to differentiate which risk factors contribute to the
development or progression of a disease state. The subjects were evaluated six to eighteen
months postpartum as to evaluate if preeclamptic participants had more adverse cardiovascular
outcomes when compared to those who had factors for metabolic syndrome. This study design
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helps the researchers to develop the cases and define the specific study populations being
evaluated.
Limitations are the retrospective nature of the study design. There can be some bias from
Heidema et al, when evaluating the data as it is known to which group the data is coming from.
The study and control groups also pose a limitation to these researchers. The study group
contains 90 participants and the control group consists of 30 participants. The variation in
participation number between these groups can lead to discrepancies when it comes to evaluation
of the results.
Aspirin effect on endothelium
The effects of aspirin on the endothelium have been vastly studied. Hashemi et al., (2016)
conducted a triple-blind randomized control trial to investigate how aspirin affects preeclamptic
patients in regard to endothelial function. Their study included the use of brachial artery flowmediated dilation analysis both during pregnancy and following delivery. The intent behind this
was to evaluate these measurements after the shear stress on the endothelium had occurred. In
this case, that shearing damage to the endothelium was caused by the high blood pressure of
preeclampsia. The findings from Spaanderman et al, (2005), also demonstrated that the
endothelial shear from preeclampsia results in hyperactive platelet activity. Therefore, one may
conclude that aspirin indirectly effects the endothelium by interrupting the process of platelet
activation. This poses another question of whether the endothelial shear versus the platelet
activation it causes pose a greater risk of cardiovascular and circulatory morbidity. This will not
be further explored as part of this review.
Hashemi et al., (2016), found that daily low dose aspirin increases flow-mediated
brachial artery dilation. These results demonstrate that endothelial function in this population
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with the intervention of low-dose aspirin (81mg/day) is improved (Hashemi et al., 2016). These
researchers attribute the improvement to the antioxidant characteristics aspirin has on platelet
function at this dose (Hashemi et al., 2016). Decreasing oxidative injury to the endothelium
theoretically would decrease platelet activation that follows endothelial injury, incidentally,
aspirin is therapeutic in both of these pathways as evidenced by Hashemi et al., (2016) and
Spaanderman et al., (2005). As evidenced by the studies done by Hashemi et al., (2016), and
Spaanderman et al., (2005), it appears that aspirin decreases cardiovascular morbidity and
mortality by action in more than one pathway in the platelet activation cascade.
Spaanderman et al., (2005), conducted a trial in which 66 formerly preeclamptic patients
were placed in groups that had comparable numbers for other variables contributing to
cardiovascular morbidity and mortality. They then further divided the patients based on their
platelet responsiveness to a low dose aspirin regimen. It does not specify whether this is a
double-blind, randomized control trial or not in which case, this can be a poor study design as the
researchers are aware of which participants are in which group. This kind of study design can
lead to increased bias when interpreting the results as the researchers are aware of which
outcomes they are looking for. Another limitation of this study is the small sample population. A
sample population of 66 participants that meet very strict exclusion criteria, is very difficult to
generalize to the general population.
One strength from Spaanderman et al., (2005), is that all women have the same inclusion
criteria. These women were then evaluated for factors that can contribute to vascular damage.
From there, their study worked to determine whether aspirin decreased platelet responsiveness in
this population. The risk factors are specific and the measurement parameters are clearly stated.
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Hashemi et al., (2016), conducted a triple-blind, randomized clinical trial. This is a strong
study design and increases the strength of the results produced. They measured flow-mediated
dilation before aspirin therapy was initiated and again following the puerperium. They utilized Ttest to compare the aspirin and control groups. Hospital registries were used to find participants
and inclusion and exclusion criteria were applied prior to inclusion in the study.
Limitations of the Hashemi et al., (2016) study are the small sample size. The sample
population was also taken from an Iranian hospital registry so the results generated would not be
able to be generalized to populations outside of Iran. Larger studies are necessary to increase the
generalizability of these results.
Long term cardiovascular outcomes following preeclampsia
Bokslag et al. (2017) evaluated the future risk of developing cardiovascular disease in
women who had preeclampsia during pregnancy. They reviewed current research in which they
found there is increased risk for this population to develop cardiovascular disease but not until
the fifth decade following preeclampsia (Bokslag et al., 2017). Their goals were to evaluate if
there is an opportunity to provide preventive therapy for these patients so they do not go on to
develop cardiovascular disease in the fifth decade following preeclampsia (Bokslag et al., 2017).
They looked at the possibility of being able to prevent cardiovascular disease in this population.
They investigated if the implementation of preventive measures within the first one to two
decades following preeclampsia will decrease the risk of these women developing cardiovascular
disease later in life. Following their research and statistical analysis, they found that 42% of the
participants who formerly had preeclampsia met their criteria for preventive measures, which
they found to be statistically significantly different from women with an uncomplicated
pregnancy (P<.0001) (Bokslag et al., 2017). Based on the findings of Bokslag et al. (2017),
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formerly preeclamptic women do not have increased risk for cardiovascular morbidity and
mortality until their fifth decade post-partum. Thus, there is a need for further research to
confirm these results, as this subgroup of women may be able to prevent future cardiovascular
events if recognized and treated accordingly.
Bokslag et al., (2017), produced a prospective observational study to assess risk of
cardiovascular disease later in life for these women. They reviewed and screened medical
records to identify women who had preeclampsia, decades ago, to form the cohort. They then
sent a questionnaire regarding signs and measurements such as blood pressure, lipid levels, etc.,
that increase risk of cardiovascular disease. They then identified a timeline of when preventive
measures would be most beneficial as defined by specific risk factors for developing
cardiovascular disease. In conclusion, they discovered many women are at risk for developing
cardiovascular disease after having preeclampsia during their pregnancies. However, these
women fall outside of the parameters to initiate preventive measures according to many various
guidelines set by preventative programs. As many of these patients have not had preventive
measures, it is difficult to make concrete conclusions about the efficacy of preventive measures
in this population, and the ability to stave off cardiovascular disease for these patients. This
group concludes that more studies need to be done to provide data on the efficacy of preventive
measures in this specific population.
Funai et al. (2005) conducted a prospective cohort study for their evaluation of the longterm mortality in patients who had preeclampsia. Their goal was to evaluate the mortality risk,
long-term, in women who had preeclampsia and were normotensive following their pregnancy.
As part of their methods, they include the Jerusalem Perinatal Study, which includes the
surveillance of patients, who met their criteria, from the three largest obstetric units in Israel. The
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Jerusalem Perinatal Study evaluates hypertensive disease in pregnancy. It gives these researchers
a database of women who had preeclampsia and fit into a longer-term follow up that has
previously been evaluated. They discovered that preeclampsia was related to higher mortality
risks (Funai et al., 2005). They then further extrapolate causes of death and make correlations
based on those findings. To gather their results, they used follow-up then did statistical analysis
on various components to their research. The median follow-up was 30 years. Their results show
that in the 24-36 years of follow up, the risk of death more than doubled in those with
preeclampsia (Funai et al., 2005). Similar to Bokslag et al., (2017), Funai et al., (2005) found that
formerly preeclamptic women had increased cardiovascular morbidity and mortality, decades
postpartum. The findings of these two, large, studies reveals there is possibly a subpopulation
that is at risk for poor future cardiovascular outcomes. There is a need for continued
investigation into this subpopulation and if these results are reproduceable as it would be prudent
for the healthcare community to prevent these poor outcomes in this group.
The strengths of this study are the design and methods. They did other analysis and due
to the similarity in results to their original model, they only present the first type of analysis they
evaluated. The cohort selected provides a broad representation that can be compared to the total
population. Also, there could not have been any bias at the time of data collection as well as
being due to the use of population-based registries that only screened for preeclampsia as an
identifier. They also have strong control of additional variables that could have contributed to
influencing mortality in this cohort.
The authors also identify areas of weakness in their study design. They did not include
other risk factors for developing cardiovascular disease, such as, obesity, diet, etc. They were
also limited in the documentation of births from 1964-1976, which was predetermined by a
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previous study. They did not have access to complete obstetric records of these individuals, so
they are not able to ascertain if this is the woman’s first pregnancy, or if it is a subsequent
pregnancy, which can alter risk of preeclampsia.
Grandi et al. (2017) conducted a cohort study to evaluate risk of future cardiovascular
disease in women who had hypertensive disorders during pregnancy. They used the Clinical
Practice Research Datalink to identify 146748 women during their first pregnancy, to develop
their cohort. From this database, they used specific diagnostic codes and blood pressure readings
to further narrow the cohort to only include women who met the criteria and were between 18
weeks gestation and the puerperium. Time-variance confounders are accounted for by use of
Marginal structural Cox models (MSM). Their results show, with a hazard ratio of 2.2, 95%
confidence interval, that the patients in this population are at a much higher risk of developing
cardiovascular disease later in life (Grandi et al., 2017). With the MSM and time-fixed analysis,
they found these results are consistent.
There are multiple strengths in this article. The first is the ability to decrease the amount
of residual confounding by a comprehensive database search that allowed the ability to include
covariables in the search. They also utilized a clinical database. This allows them to include
individuals who meet their definitions for exposure and outcomes and limits those who were not
classified correctly in the database. This study design allows them to also account for women
who had more than one pregnancy.
Despite the strong study design, these authors also faced some limitations. In the
database used, gestational age was not readily stated which could increase the risk of them
misclassifying individuals. This database also included records provided by a primary care
provider. Individuals who meet criteria but are followed only by an obstetrician or a midwife
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may not be included in the data. This can lead to a selection bias and will skew the results. The
majority of individuals included in the cohort also only had one pregnancy despite the selection
criteria being open to include those with multiple pregnancies, which would decrease the ability
for this information to be generalized to multiparous women who had preeclampsia.
Hermes et al. (2010) conducted a cohort study. The goal of this study is to identify
modifiable risk factors that predispose these patients to development of cardiovascular disease in
the future. They used the HYPITAT study upon which to develop their cohort. The participants
chosen from this study will be available for follow up by these researchers. The present study
was conducted to evaluate evidence of screening women who had term preeclampsia, two and a
half years after pregnancy, for cardiovascular risk.
A limitation in their evaluation is regarding the limited sample size which resulted in
some statistical issues. They had to further utilize Chi-squared for comparison groups. Their
statistical evaluation further includes logistic regression analysis to further extrapolate the
information from the data collected. They conclude that data for this population regarding longterm risk for developing cardiovascular disease, is minimal, and they are hopeful to provide
information that can be generalized to those who had term gestational hypertensive disorders of
pregnancy. These authors had no conflicts of interest.
Leslie et al. (2016) did a systematic review and meta-analysis. They conducted this
review to compile recommendations for reducing risk and increasing patient awareness of their
future risks, in this demographic. For their systematic review, they utilized MEDLINE, Scopus,
CINAHL, ISI Web of Knowledge, and Chochrane databases for their search. Inclusion criteria
were defined as: English, peer reviewed, specified time frame, and relationship between
hypertensive disorders of pregnancy and future risk of cardiovascular disease. The total inclusion
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from the 48 qualified reviews resulted in 3,598,601 women meeting the inclusion criteria. They
found that gynecology clinics were less likely to identify new-onset hypertension, than primary
care clinics (22% vs 38%; P<.0001) (Leslie et al., 2016). They discovered the literature shows
that women who had preeclampsia have a two times increased risk of developing cardiovascular
disease and mortality. The increased risk of mortality was lower when the baby was born at 37
weeks or later (RR, 0.98; 95%CI, 0.5-1.92) (Leslie et al., 2016).
A strength of this systematic review and meta-analysis is the sample size. These
findings are more likely to be generalized to other women who have hypertensive disorders
while pregnant, when trying to estimate their future cardiovascular risk factors. They included all
relevant studies from a vast variety of databases that were searched. Their inclusion criteria were
clearly defined and allowed for accurate appropriateness when combining these results. A
limitation remains in providing conclusive evidence regarding preventative therapy for the
development of future cardiovascular disease. There continues to be a need for more data
researching those answers.
Mannisto et al. (2013) conducted a population-based prospective cohort evaluation of
long-term chronic disease risk following hypertensive disorder during pregnancy. Their goals
were to evaluate women’s subsequent risk of chronic diseases following hypertensive disorder
during pregnancy. They specifically looked at the Northern Finland Birth Cohort of 1966. They
were able to get clinical data such as blood pressure, from prenatal records. They then
investigated additional diagnoses utilizing Finnish registries. For statistical analysis, they
performed hazard ratios with 95% confidence intervals to compare the risk of a hypertensive vs
normotensive pregnant patient.
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One of the most notable strengths of this review is the outstanding sample size they
were able to achieve that met their inclusion criteria. They also clearly defined exclusion criteria
through each phase as it was discovered that some individuals who originally met inclusion
criteria were missing important data measurements such as blood pressure. Other strengths
include the control of variables even down to position of the patient when the blood pressure was
taken to provide even more clarity in comparing the data. Limitations of this review include
misclassification due to the evolution of diagnostic criteria for gestational hypertension over the
interim. No disclosures are included by the authors.
For statistical analysis, due to the prospective nature of this study, they used Cox
regression analysis to evaluate the impact hypertension had on future morbidity and mortality.
They also included hazard regression and confidence intervals when evaluating their results.
Theilen et al. (2016) conducted a retrospective cohort study with the goal of evaluating
if women who had hypertensive disorders when pregnant, have a higher risk of early mortality.
The cohort they evaluated were women with singleton pregnancies between 1939 and 2012.
They used the Utah Population Database to identify mothers who singleton pregnancies.
Inclusive criteria were applied to further narrow and specify the appropriate individuals for the
study. The women included were those who had a hypertensive disorder of pregnancy in a
singleton pregnancy and continued to reside in Utah for one year following the birth. Specific
exclusion criteria are included as well to further increase the specificity of the cohort selected.
After applying inclusion and exclusion criteria, they had 2,083,331 eligible pregnancies upon
which to further evaluate. They also had 123,140 normotensive women upon who to provide a
comparison (Theilen et al., 2016). After discerning all-cause mortality rates, they divided the
women with hypertensive disorders of pregnancy, further into subgroups and assessed mortality
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rates based on individual hypertensive disorders that occurred during the pregnancies of these
individuals.
This is a retrospective study which poses both strengths and weaknesses for the
researchers. Additional limitations include the possibility of misclassification as well as possible
selection bias. Confounding residuals can skew the interpretation of the results as well. Although
there were some weaknesses identified, there are strengths to this article as well. This includes
the retrospective design which allows a more longitudinal assessment of how preeclampsia
effects cardiovascular and chronic health outcomes in the long term. By using a retrospective
design, researchers gather the information and make associations between those who had
preeclampsia and increased risk of chronic health outcomes in the decades to come, when
compared to their normotensive counterparts.
Wikstrom et al. (2005) conducted a cross-sectional, population-based study. The goal of
their study was to investigate if women who had gestational hypertensive disease had increased
risk of developing ischemic heart disease later in life. They used the Swedish Medical Birth
Register for definition of the study population. Specifically, they reviewed the period between
1973-1982. This cohort contains 403,550 women who gave birth in Sweden during this time
frame. Of the main cohort, 207,054 women who were analyzed separately due to giving birth to
a second child within the specified time frame (Wikstrom et al., 2005). Age, hospital and
socioeconomic status were identified as possible confounders. They calculated incidence rate
rations (IRRs) and 95% confidence intervals and treated age as a continuous variable. The
adjusted IRR for ischemic heart disease in women with hypertension during multiple pregnancies
was statistically significantly increased compared to women who only had hypertension during
their first pregnancy (P<.044) (Wikstrom et al., 2005).
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One strength of this cross-sectional population-based study was that there were very
few losses to follow up due to the nationwide nature of the study. This group felt this is due to
the low number of home deliveries that are performed in Sweden. With this database, they were
able to evaluate both hospitalizations and deaths from ischemic heart disease, in this population.
The first limitation identified is the long follow up period. They also suspect there may have
been some underreporting of hypertensive disease that was thought to be milder. Another
limitation identified by this research group is their inability to account for BMI and smoking
habits, both contributors to the development of heart disease, as these variables were not reported
to the national registry in Sweden.
Aspirin use to decrease the risk of ischemic stroke, postpartum
Tang et al. (2010) conducted a review that includes articles looking at the timeframe
between pregnancy and the puerperium, in which stroke risk is increased in patients who have
preeclampsia and are pregnant, or in the puerperium, and management to decrease this risk. To
form conclusions and recommendations regarding management, they reviewed the
epidemiology, causes, and treatment. They dissected their review of the literature and state the
key issues. They found there is an increased risk of stroke during the puerperium. There is a
range in the incidence of stroke during this time frame. The literature demonstrates stroke is
related to 5-10% of maternal death (Tang et al., 2010). This is important as they also found
hypertensive diseases of pregnancy contribute 25-45% of pregnancy-related stroke (Tang et al.,
2010). This review finds that preeclampsia predisposes women to higher risk of cardiovascular
diseases in later decades of life.
In this review the authors failed to identify their search methods which will decrease the
strength of the review as much of the conclusions are then based on correlation and expert
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clinical opinion. The credibility is decreased as bias may be included in their concluding
opinions. They identify that the current management for these patients may not be as safe as once
thought and more research needs to be done to provide more data. The design of such studies
also needs to be strengthened to allow providers to form better conclusions about the
management of these patients and decreasing future risk of cerebrovascular and cardiovascular
disease.
Van Alebeek et al. (2018) aim to review data and literature on how to manage ischemic
stroke in pregnancy and the puerperium, with aspirin. These authors strived to include clinically
relevant data, from the limited pool of data that is available. The goals of their review are to
provide a guide for the management of stroke in this population (Van Alebeek et al., 2018). They
review the pathophysiology and epidemiology of preeclampsia. Then Van Alebeek et al., (2018)
incorporate current knowledge on the effects of aspirin in the management and prevention of
ischemic stroke in women with preeclampsia. They also include discussion about other
anticoagulant and antithrombotic therapies in comparison to aspirin therapy for the management
of stroke in pregnant and women in the puerperium (Van Alebeek et al., 2018).
There are scarce studies done on ischemic stroke in this population. One of the
limitations to this review is the lack of primary data available. Another limitation is the lack of
high-quality observational studies available to review. These reviewers could also increase the
strength of their review by including their search methods and why certain articles were excluded
or not. Many of their conclusions are based on their expert opinions.
Aspirin effect on long term cardiovascular outcomes following preeclampsia
Sarma et al. (2016) conducted a literature review with the goal of evaluating the use of
low-dose aspirin for prevention of cardiovascular disease in men and women and low dose
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aspirin for prevention of preeclampsia. They first discuss how sex differences influence the
physiologic response to aspirin. Through evaluation of current literature they discovered that the
platelet reaction of women is higher than men, although both sexes achieve platelet suppression
with aspirin therapy (Sarma et al., 2016). They evaluated primary prevention with aspirin.
Specifically, they evaluate the efficacy of aspirin for primary prevention of cardiovascular
disease and stroke in women. The benefit of aspirin therapy and decreased risk of stroke or
cardiovascular events was time dependent. The bleeding risks of using aspirin for primary
prevention began to outweigh the benefits when evaluating 15-year outcomes. Through their
review, they found, in a WHS meta-analysis, that in 100,000 patients, there is a 12% decrease in
cardiovascular events and a 17% decrease in stroke, however, with further evaluation, absolute
benefit of aspirin therapy was 0.3%, showing little benefit (Sarma et al., 2016). Thus, there was
not a statistically significant improvement in cardiovascular events or stroke prevention when
patients took aspirin prophylactically.
They then evaluate the use of aspirin therapy for secondary prevention of cardiovascular
events and stroke. When used for secondary prevention, aspirin provided a 14% reduction in allcause mortality (hazard ratio 0.86), over a follow up period of 6.5 years (Sarma et al., 2016).
Their review of the literature concludes that aspirin continues to be the standard of care for
secondary prevention of cardiovascular events. They also speculate that if it is possible to
prevent preeclampsia, this may result in a decrease in incidence of cardiovascular disease later in
life since women with preeclampsia have a higher risk of developing cardiovascular disease later
in life (Sarma et al., 2016). This is an area that warrants further investigation and research.
McNeil et al., (2018), designed a randomized, double-blind, placebo-controlled study, to
further investigate whether aspirin has a beneficial effect on the primary prevention of
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cardiovascular disease. Their study was specifically targeted toward an elderly population. They
evaluated a sample population of participants over the age of 70 who were from the US or
Australia. Specific inclusion and exclusion criteria are listed in detail. Statistical analysis was
done using Cox proportional-hazard ratios. During participant follow up, the results produced
demonstrate that in the aspirin group, 7.8 major cardiovascular events occurred for every 1000
person-years, compared to 8.8 major cardiovascular events for every 1000 person-years in the
placebo group (McNeil, et al., 2018). This was statistically insignificant (hazard ratio, 0.89; 95%
CI, 0.77 to 1.03) (McNeil, et al., 2018). However, in the aspirin group, the risk for major
hemorrhagic events was 8.6 per 1000 person-years, whereas the placebo group produced 6.2
hemorrhagic events per 1000 person-years (McNeil, et. al., 2018). The results produced by this
study have changed the recommendations for aspirin use in the elderly population (>70 years of
age), for primary prevention of cardiovascular disease.
The findings of Sarma et al (2016) and McNeil et al (2018) suggest that when used for
primary prevention of cardiovascular disease, the long-term risk for bleeding or hemorrhage with
aspirin therapy, outweighs the benefit of decreased cardiovascular and stroke outcomes. Further
research needs to be done specifically for the post-preeclamptic population. Sarma et al. (2016),
designed a study looking at women specifically, as they have historically been under represented
in the sample populations of the studies in the literature. McNeil et al. (2018) also investigated an
underrepresented population in these studies, the elderly. Based on the findings that increase in
cardiovascular risks do not present until the third to fifth decade following preeclampsia, it is
reasonable to speculate that these women would be in their seventh decade of life or beyond.
Based on the information provided by these two studies, it appears that we first must identify
whether preeclampsia places these women in the category of primary or secondary prevention.
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Further studies are required to investigate whether there is a therapeutic intervention that
decreases the future cardiovascular risk in this population.
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Discussion
Preeclampsia is a condition which affects approximately 3-7% of pregnancies (Hashemi
et al., 2016 and Sarma et al, 2016). This condition predisposes both mother and fetus to increased
risks during the third trimester of pregnancy. It is found that these women also have increased
risk for cardiovascular events or ischemic stroke into the puerperium. It remains a mystery as to
the cause of preeclampsia. Many researchers continue to hypothesize and investigate the cause of
preeclampsia and what predisposes these women to getting this condition during their
pregnancies.
There is evidence of increased risk for thrombotic or ischemic events in these mothers
during pregnancy. The current USPSTF recommendation is for these women to take 81 mg
Aspirin, daily, for the second and third trimesters of their pregnancy, to decrease adverse
outcomes from preeclampsia (Grade B recommendation). However, there remains a question
regarding the future cardiovascular risk in this population, and if so, is there a population going
untreated in which we could decrease cardiovascular morbidity and mortality later in life?
Does continued aspirin use in postpartum women, who had preeclampsia during
pregnancy, decrease future cardiovascular morbidity and mortality outcomes?
To investigate what benefits aspirin may have in preventing or decreasing cardiovascular
morbidity and mortality in women who formerly had preeclampsia, we first need to understand
how aspirin and preeclampsia effect vascular physiology.
Evaluating the pathophysiology of preeclampsia in relation to endothelial health is
difficult as there is only a small number of studies available. The information available is
lacking. It has also been a challenge for researchers to differentiate whether maternal or placental
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mechanisms are the cause of preeclampsia. Chambers et al, (2001) designed a study that
evaluated brachial artery flow index, in women with an average time of 3 months from delivery,
in order to isolate maternal mechanisms that may contribute to endothelial physiology in
preeclampsia. It was also found that preeclampsia history is also a greater indicator of future
development of metabolic syndrome, compared to obesity (Heidema et al., 2015). The
development of metabolic syndrome in previously preeclamptic women may suggest some
degree of persistent endothelial dysfunction. The Mayo clinic defines metabolic syndrome as, “a
cluster of conditions—increased blood pressure, high blood sugar, excess body fat around the
waist, and abnormal cholesterol or triglyceride levels.” The pathophysiology that occurs during
metabolic syndrome has strong connections to future cardiovascular and circulatory pathology.
Spaanderman et al. (2005), also found that preeclampsia predisposes these women to have
greater platelet reactivity. These conclusions demonstrate that preeclampsia has some effect on
the endothelium, either directly or indirectly, as in the case with platelet reactivity. There
continues to be a need for further research investigating the effect preeclampsia has on the
endothelium as the discovery of these mechanisms can lead further research into the risks and
benefits of preventative therapy for this population.
Spaanderman et al., (2005) also concluded that aspirin decreases platelet activity
following endothelial injury. This demonstrates that aspirin indirectly affects the physiology of
the endothelium by prevent the clotting cascade and platelet activity. Aspirin may also effect the
endothelium by its antioxidant characteristics. This suggests that aspirin can decrease the
oxidative damage imparted on the endothelium, particularly by the shear stress incurred during
preeclampsia, from the high blood pressure that defines this disease (Hashemi et al., 2016). They
created a randomized control trial in which endothelial dysfunction was improved, as measured
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by brachial artery mediated dilation, following aspirin therapy at low doses, 81 mg (Hasemi et
al., 2016). The findings of Hashemi et al (2016) and Spaanderman et al (2005) suggest that
aspirin has multiple characteristics that alter endothelial physiology. Aspirin is theorized to both
interact with the oxidative damage to the endothelium and decreasing the platelet activity
following endothelial injury. This is important to consider when investigating whether
preeclamptic women would benefit from this type of therapy to decrease future cardiovascular
morbidity and mortality. However, there continues to be a need for further research investigating
the effects of aspirin on the endothelium, specifically, as preeclampsia poses a shearing stress to
the endothelium, and what the implications of such an injury are.
The data investigating the long-term effects on cardiovascular morbidity and mortality
following preeclampsia continue to be lacking. There are a handful of various reviews available,
however, this information can be weak as much of the conclusions in these literature studies are
based on the expert or clinical opinion of the authors. From the available studies that have been
conducted looking at this potential problem, only a few are of high quality and an appropriate
sample size in which to make broad generalizations to this population. Amongst these
researchers, it is found that increased cardiovascular morbidity and mortality following
preeclampsia is not encountered until approximately 30 to 50 years following the diagnosis of
preeclampsia (Funai et al, 2005 and Bokslag et al, 2017). Hermes et al, (2010) attempted to
discern if there are risk factors for cardiovascular disease following preeclampsia, in which
modification of these risk factors might possibly decrease future cardiovascular morbidity and
mortality. Their sample size was quite limited and thus it is difficult to make conclusions based
on their information alone. Following Chi squared regression analysis, they concluded that the
increased risk to this population was minimal (Hermes et al., 2010).
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It is very difficult to interpret the results of the limited number of studies available as
there are a number of differences between them. The production of a sample population based on
a hospital database will only provide information for the population within that country or
region. It would not be astute of us as providers to apply information regarding future
cardiovascular morbidity and mortality, from Sweden, to people in India.
It is also difficult to ascertain whether preeclampsia is the sole variable leading to the
increased cardiovascular morbidity and mortality in this population. By thirty to fifty years
following preeclampsia, these women could have been exposed to many other variables that
increase risk of cardiovascular disease later in life. There is a need for more studies that target
this population and also control for other variables that contribute to increases cardiovascular
morbidity and mortality.
Overall, when trying to evaluate if preeclampsia predisposes women to increased future
cardiovascular morbidity and mortality, there continues to be a need for stronger studies upon
which to base practice recommendations. There may possibly be a significant number of patients
who fit within this population, who are at increased risk, unbeknownst to the provider and/or
patient, for cardiovascular events, in which we could potentially provide preventative therapies
to improve their future health. Again, these studies are weakened by their reliance on expert
opinions and small sample sizes. The few solid studies available demonstrate that there is, in
fact, a statistically significant increase in cardiovascular risk, in the third to fifth decades
following preeclampsia. This information demonstrates the need for further research so we, as
providers, can appropriately care for these women for the prevention of future cardiovascular
morbidity and mortality in these patients. Future studies should also include controls for other
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factors that contribute to increased cardiovascular morbidity and mortality, such as, smoking,
obesity, family history, physical inactivity, etc.
When investigating the effect of aspirin on future risk of ischemic stroke, following
preeclampsia, the data is limited. Tang et al (2010) conducted a study in which the inclusion
criteria included a very narrow time frame following preeclampsia. Their study specifically
focused on the puerperium and decreasing the incidence of stroke in the first six weeks following
delivery, in women who had preeclampsia. It is difficult to apply this information to women for
long term treatment and prevention. They also state preeclampsia leads to a significant increase
in future cardiovascular risk, (Tang et al., 2010), however, the data and statistics to support this
information are not included in their commentary.
High dose aspirin for decreased risk of ischemic stroke postpartum, was also investigated
by van Alebeek et al, (2018). Their data suggest that the treatment in this population is left to
expert opinion and is not yet supported by clinical trials (van Alebeek et al, 2018). There is
evidence to support the use of aspirin therapy following an event of an ischemic stroke in women
with preeclampsia, however, this data is applied to women who are still pregnant and into the
puerperium, not at preventing a longer term risk of ischemic stroke (van Alebeek et al, 2018). It
is important for future studies to identify if they are investigating aspirin therapy as primary or
secondary prevention of future ischemic stroke morbidity and mortality in the post preeclamptic
population. Thus far, much of the information provided in regard to ischemic stroke risk related
to preeclampsia, primary focuses on the second and third trimesters and into the puerperium,
however, lacks investigation into longer term studies of these risks.
Finally, we also included a look at the information that evaluated the effect of aspirin
therapy on long term cardiovascular morbidity and mortality, following preeclampsia. It was
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discovered by Sarma et al (2016) that women are lacking in the representative samples regarding
research that has been done regarding cardiovascular morbidity and mortality and therapy to
reduce these statistics. They aimed to research the physiological differences amongst men and
women that may contribute to why reduction in cardiovascular events is greater in men than in
women (Sarma et al, 2016). Upon conclusion of their studies, their data was inconclusive
regarding the use of aspirin for primary prevention of cardiovascular morbidity and mortality in
this population. They also speculate that if aspirin therapy is used after the 12th week of
gestation, this will theoretically reduce the risk of the development of preeclampsia in high risk
patients, which will in turn decrease the future cardiovascular risk in these women if
preeclampsia is prevented (Sarma et al, 2016).
Investigation into aspirin effect on elderly populations is also warranted, as we previously
remarked about increased cardiovascular risk following preeclampsia, not being significant until
the third to fifth decades following preeclampsia. McNeil et al (2018), wanted to extrapolate the
data regarding this very question. They designed a large, double blind, randomized control study
in which their target population were individuals who were greater than the age of 70 years. The
information from both Sarma et al (2016), and McNeil et al, (2018) demonstrate that long term
aspirin use for the prevention of cardiovascular risks may in fact be more harmful than the
perceived benefit it produces. McNeil et al (2018), found that there was a statistically
significantly increased risk for major hemorrhage (P<.001), when compared to the benefit it
provided, which was not found to be statistically significant. The hazard ratio for prespecified
end points in this case was 0.95, by which McNeil et al (2018) conclude contradicts a major
protective effect of aspirin (McNeil et al, 2018).
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Trying to evaluate if therapeutic means, specifically aspirin, in the prevention of future
cardiovascular morbidity and mortality, following preeclampsia is a difficult undertaking. There
are many different unknown variables that need to be considered when trying to look only at
these two factors.
The first hurdle is that the scientific community is largely uncertain as to the specific
pathophysiology behind preeclampsia. The first step in determining if these women are at
increased risk, and if we can prevent this increased risk, is to definitively understand the
underlying mechanisms of preeclampsia. This understanding would provide researchers with a
target at which to investigate if it is contributing to future cardiovascular risk. Understanding the
underlying pathophysiology of preeclampsia would also help to lead the scientific community
toward a safe therapy, both for mother and fetus, that would decrease the incidence of
preeclampsia.
The second hurdle is to determine, with certainty, as to whether this population is at risk
for future increased cardiovascular morbidity and mortality. As medical professionals, it would
be unwarranted to prophylactically treat these women if in fact, they do not have a greater risk
for future cardiovascular morbidity and mortality. The research included in this review seems to
point in the direction that this population of women have a future risk for increased
cardiovascular morbidity and mortality. However, there is a need for more studies and more long
term studies with large sample sizes to evaluate these women for their future risk of developing
cardiovascular morbidity and mortality. It would be astute of these researchers to also control for
other variables that contribute to cardiovascular disease such as smoking, obesity, increased
waist circumference, family history and genetic inputs, etc. The research that is necessary to
determine if these women are at increased risk would control for these variables in an effort to
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extrapolate preeclampsia as the primary indicator for future increased cardiovascular morbidity
and mortality.
From the data available, it suggests that these women are at risk for future increased
cardiovascular morbidity and mortality. The data also suggests that using aspirin for prophylaxis
may be contraindicated as its long term use increases the risk of bleeding and hemorrhage to
such an extent that it does not outweigh the cardiovascular benefits. Further research is necessary
to solidify the conclusions that this population is at risk for future increased cardiovascular
morbidity and mortality.
Amongst the science community, there is a great deal of research that is still necessary to
determine how we, as providers, would best serve our post-preeclamptic patients. There may
possibly be a whole population in which we are unaware of their increased risks. The data is very
limited in this population. There are also many factors that may be at play and the research that
digs in and separates the different angles at which to approach this question are very limited.
Among the limited amount of studies we have available, the sample sizes are often too small and
limited, which prevents the application of this information to the general population at large.
Many of these studies are also inconclusive which further limits the data pool amongst which to
base practice and treatment practices.
The information that is currently available is only a start. There is much more work to be
done in order to provide the best healthcare service to these patients. We have a duty as medical
professionals to continue to investigate whether this population is at increased risk. We also have
a duty to continue to investigate safe interventions to prevent and decrease the future increased
risk for cardiovascular morbidity and mortality in this population.
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Clinical Application
The clinical implications of this topic are important as there may be a subset of the
population that is at increased risk for future cardiovascular morbidity and mortality, that are
currently untreated. There are multiple parts to solving this question, that require further
research. Some of these questions include the safety of aspirin for prophylaxis in this population,
does preeclampsia indeed increase future cardiovascular morbidity and mortality and, is there
potentially a different therapy that is beneficial for prophylaxis in this population. It would be
wise to first extrapolate if preeclampsia increases future morbidity and mortality. This can be
difficult due to the longevity needed to complete such a study. A study design that is this drawn
out may be more prone to losing subjects to follow up, which will skew the results. This
information is important because if in fact preeclampsia does increase cardiovascular morbidity
and mortality in these women, appropriately treating these women could decrease the burden on
the healthcare system and save healthcare dollars by preventing major cardiovascular events.
With new evidence that is leading to the evolution of aspirin recommendations for
prophylaxis of cardiac or ischemic events in adults greater than 50 years old, more evidence is
needed to evaluate the safety of aspirin as prophylaxis for women who were previously
preeclamptic. If it turns out that preeclampsia increases future cardiovascular morbidity and
mortality, it would be wise to determine if in fact, aspirin is the best prophylactic treatment for
this demographic. Is there a different therapy that is more efficacious and has a lower risk of
bleeding?
These are questions that we currently don’t know the answers to, or the answers we have
been provided with are not strong enough to stand on their own. There have been studies done,
however, many are of poor design and rely on expert opinion upon which the conclusions are
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made. Others have small sample sizes or the sample population is not able to be generalized to
the greater population. Many of the studies done are not recent, so it may be difficult to
generalize these findings to the general populations today, with the medical and health
advancements that have been made.
Again, determining the answers to these questions, and providing sound evidence is
important as healthcare providers may not be treating an at-risk demographic. Identifying the
risks posed to this population and providing the appropriate treatment may not only benefit the
health of the patient, it can decrease healthcare dollars and the burden placed on the healthcare
system by potentially preventing a major cardiovascular event.
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